CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade Verve Therapeutics, Inc. - VERV CFD

    12.46
    8.07%
    • Summary
    • Historical Data
    • Events
    • Income Statement
    • Balance Sheet
    • Cash Flow
    • Ownership
    Trading Conditions
    Spread 0.07
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026346 %
    Charges from full value of position ($-5.01)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026346%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.004124 %
    Charges from full value of position ($0.78)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.004124%
    Overnight fee time 22:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Verve Therapeutics Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* 11.53
    Open* 11.84
    1-Year Change* -44.49%
    Day's Range* 11.84 - 13.2
    52 wk Range 8.22-24.69
    Average Volume (10 days) 3.60M
    Average Volume (3 months) 29.66M
    Market Cap 729.33M
    P/E Ratio -100.00K
    Shares Outstanding 63.75M
    Revenue 7.63M
    EPS -3.10
    Dividend (Yield %) N/A
    Beta -100.00K
    Next Earnings Date N/A

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    • Last Week
    • Last Month
    • Last Year
    • Last two Years
    • Max
    • Daily
    • Weekly
    • Monthly
    Date Close Change Change (%) Open High Low
    Dec 5, 2023 11.53 0.01 0.09% 11.52 11.80 11.30
    Dec 4, 2023 11.97 0.40 3.46% 11.57 12.20 11.33
    Dec 1, 2023 11.76 0.63 5.66% 11.13 11.77 10.73
    Nov 30, 2023 11.24 0.01 0.09% 11.23 11.75 11.11
    Nov 29, 2023 11.16 0.59 5.58% 10.57 11.96 10.55
    Nov 28, 2023 11.89 0.36 3.12% 11.53 11.98 11.18
    Nov 27, 2023 11.52 -0.75 -6.11% 12.27 12.27 11.31
    Nov 24, 2023 12.08 0.00 0.00% 12.08 12.55 11.93
    Nov 22, 2023 12.01 0.43 3.71% 11.58 12.26 11.50
    Nov 21, 2023 11.41 -0.67 -5.55% 12.08 12.11 11.32
    Nov 20, 2023 12.32 0.49 4.14% 11.83 12.96 11.58
    Nov 17, 2023 11.70 0.74 6.75% 10.96 11.78 10.82
    Nov 16, 2023 10.94 -0.54 -4.70% 11.48 11.57 10.56
    Nov 15, 2023 11.45 0.48 4.38% 10.97 12.71 10.88
    Nov 14, 2023 10.72 0.67 6.67% 10.05 10.73 9.84
    Nov 13, 2023 9.24 -0.24 -2.53% 9.48 9.57 8.21
    Nov 10, 2023 15.66 -0.11 -0.70% 15.77 16.19 14.88
    Nov 9, 2023 16.00 -0.83 -4.93% 16.83 17.57 15.71
    Nov 8, 2023 16.69 -2.00 -10.70% 18.69 18.69 16.54
    Nov 7, 2023 18.65 2.89 18.34% 15.76 20.07 15.76

    Verve Therapeutics, Inc. Events

    Time (UTC) Country Event
    No events scheduled
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019
    Total revenue 1.941 0 0 0
    Total Operating Expense 167.628 87.067 40.627 13.642
    Selling/General/Admin. Expenses, Total 37.533 18.865 5.256 2.498
    Research & Development 130.095 68.202 35.371 11.144
    Operating Income -165.687 -87.067 -40.627 -13.642
    Interest Income (Expense), Net Non-Operating 6.867 0.142 0.162 0.278
    Other, Net 1.486 -33.389 -5.239 -5.933
    Net Income Before Taxes -157.334 -120.314 -45.704 -19.297
    Net Income After Taxes -157.387 -120.314 -45.704 -19.297
    Net Income Before Extra. Items -157.387 -120.314 -45.704 -19.297
    Net Income -157.387 -120.314 -45.704 -19.297
    Income Available to Common Excl. Extra. Items -157.387 -120.314 -45.704 -19.297
    Income Available to Common Incl. Extra. Items -157.387 -120.314 -45.704 -19.297
    Diluted Net Income -157.387 -120.314 -45.704 -19.297
    Diluted Weighted Average Shares 54.0237 48.5117 46.1104 46.1104
    Diluted EPS Excluding Extraordinary Items -2.9133 -2.4801 -0.99119 -0.4185
    Dividends per Share - Common Stock Primary Issue 0 0
    Diluted Normalized EPS -2.9133 -2.4801 -0.99119 -0.4185
    Revenue 1.941
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 2.093 1.404 1.012 0.929 0
    Total Operating Expense 60.676 59.663 48.722 44.789 42.192
    Selling/General/Admin. Expenses, Total 13.416 12.553 11.438 9.592 9.067
    Research & Development 47.26 47.11 37.284 35.197 33.125
    Operating Income -58.583 -58.259 -47.71 -43.86 -42.192
    Interest Income (Expense), Net Non-Operating 5.438 5.546 4.501 1.976 0.308
    Other, Net -0.662 0.738 2.177 -3.306 0.938
    Net Income Before Taxes -53.807 -51.975 -41.032 -45.19 -40.946
    Net Income After Taxes -53.983 -51.975 -41.085 -45.19 -40.946
    Net Income Before Extra. Items -53.983 -51.975 -41.085 -45.19 -40.946
    Net Income -53.983 -51.975 -41.085 -45.19 -40.946
    Income Available to Common Excl. Extra. Items -53.983 -51.975 -41.085 -45.19 -40.946
    Income Available to Common Incl. Extra. Items -53.983 -51.975 -41.085 -45.19 -40.946
    Diluted Net Income -53.983 -51.975 -41.085 -45.19 -40.946
    Diluted Weighted Average Shares 61.954 61.7874 61.5465 57.2071 48.6749
    Diluted EPS Excluding Extraordinary Items -0.87134 -0.84119 -0.66754 -0.78994 -0.84121
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.87134 -0.84119 -0.66754 -0.78994 -0.84121
    Revenue 2.093 1.404 1.012 0.929
    • Annual
    • Quarterly
    2022 2021 2020 2019
    Total Current Assets 563.159 367.128 73.966 19.054
    Cash and Short Term Investments 554.808 360.442 72.112 18.782
    Cash & Equivalents 115.412 64.33 8.993 2.986
    Short Term Investments 439.396 296.112 63.119 15.796
    Prepaid Expenses 7.339 6.686 1.854 0.272
    Total Assets 679.223 384.124 78.413 21.647
    Property/Plant/Equipment, Total - Net 110.655 9.063 3.984 2.358
    Property/Plant/Equipment, Total - Gross 115.642 11.396 4.782 2.467
    Accumulated Depreciation, Total -4.987 -2.333 -0.798 -0.109
    Other Long Term Assets, Total 5.409 7.933 0.463 0.235
    Total Current Liabilities 35.095 22.024 7.315 3.553
    Accounts Payable 2.424 7.077 0.036 2.411
    Accrued Expenses 32.671 14.947 7.189 1.111
    Notes Payable/Short Term Debt 0 0 0 0
    Other Current Liabilities, Total 0 0.09 0.031
    Total Liabilities 128.291 26.772 17.162 15.72
    Total Long Term Debt 0 0 0 0
    Other Liabilities, Total 93.196 4.748 9.847 12.167
    Total Equity 550.932 357.352 61.251 5.927
    Redeemable Preferred Stock 0 0 125.16 25.48
    Common Stock 0.062 0.049 0.003 0.002
    Additional Paid-In Capital 895.801 544.381 2.616 1.268
    Retained Earnings (Accumulated Deficit) -344.237 -186.85 -66.536 -20.832
    Unrealized Gain (Loss) -0.694 -0.228 0.008 0.009
    Total Liabilities & Shareholders’ Equity 679.223 384.124 78.413 21.647
    Total Common Shares Outstanding 61.7308 48.5117 46.1104 46.1104
    Total Receivables, Net 1.012
    Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
    Total Current Assets 498.261 473.066 517.787 563.159 561.63
    Cash and Short Term Investments 485.226 462.476 508.687 554.808 550.71
    Cash & Equivalents 78.37 70.042 83.746 115.412 277.019
    Short Term Investments 406.856 392.434 424.941 439.396 273.691
    Prepaid Expenses 9.89 8.497 7.696 7.339 9.991
    Total Assets 612.407 589.131 634.376 679.223 673.355
    Property/Plant/Equipment, Total - Net 107.844 110.018 111.056 110.655 106.491
    Property/Plant/Equipment, Total - Gross 116.729 117.429 117.17 115.642 110.703
    Accumulated Depreciation, Total -8.885 -7.411 -6.114 -4.987 -4.212
    Other Long Term Assets, Total 6.302 6.047 5.533 5.409 5.234
    Total Current Liabilities 34.575 33.031 33.552 35.095 29.018
    Accounts Payable 1.054 3.146 3.372 2.424 0.465
    Accrued Expenses 33.521 29.885 30.18 32.671 28.553
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total
    Total Liabilities 152.038 123.909 124.9 128.291 125.412
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 117.463 90.878 91.348 93.196 96.394
    Total Equity 460.369 465.222 509.476 550.932 547.943
    Redeemable Preferred Stock 0 0 0 0 0
    Common Stock 0.064 0.062 0.062 0.062 0.061
    Additional Paid-In Capital 956.855 916.109 905.863 895.801 851.954
    Retained Earnings (Accumulated Deficit) -495.953 -450.195 -396.212 -344.237 -303.152
    Unrealized Gain (Loss) -0.597 -0.754 -0.237 -0.694 -0.92
    Total Liabilities & Shareholders’ Equity 612.407 589.131 634.376 679.223 673.355
    Total Common Shares Outstanding 63.7371 62.0643 61.863 61.7308 60.4432
    Total Receivables, Net 3.145 2.093 1.404 1.012 0.929
    • Annual
    • Quarterly
    2022 2021 2020 2019
    Net income/Starting Line -157.387 -120.314 -45.704 -19.297
    Cash From Operating Activities -122.332 -77.88 -35.265 -7.442
    Cash From Operating Activities 2.804 1.535 1.328 0.106
    Non-Cash Items 23.871 43.811 6.469 9.088
    Changes in Working Capital 8.38 -2.912 2.642 2.661
    Cash From Investing Activities -155.955 -239.098 -51.127 -12.758
    Capital Expenditures -13.232 -4.359 -3.424 -1.857
    Other Investing Cash Flow Items, Total -142.723 -234.739 -47.703 -10.901
    Cash From Financing Activities 328.956 377.089 92.627 17.954
    Issuance (Retirement) of Stock, Net 329.739 379.939 92.627 18.04
    Issuance (Retirement) of Debt, Net 0 0 -0.086
    Net Change in Cash 50.669 60.111 6.235 -2.246
    Financing Cash Flow Items -0.783 -2.85
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -51.975 -157.387 -116.302 -71.112 -30.166
    Cash From Operating Activities -49.096 -122.332 -89.44 -60.265 -33.507
    Cash From Operating Activities 1.127 2.804 1.879 1.162 0.514
    Non-Cash Items 5.063 23.871 19.857 9.468 3.755
    Changes in Working Capital -3.311 8.38 5.126 0.217 -7.61
    Cash From Investing Activities 15.392 -155.955 12.358 67.874 60.092
    Capital Expenditures -3.375 -13.232 -8.264 -5.627 -2.908
    Other Investing Cash Flow Items, Total 18.767 -142.723 20.622 73.501 63
    Cash From Financing Activities 2.038 328.956 289.358 0.95 0.505
    Issuance (Retirement) of Stock, Net 2.103 329.739 289.963 0.95 0.505
    Net Change in Cash -31.666 50.669 212.276 8.559 27.09
    Financing Cash Flow Items -0.065 -0.783 -0.605 0
    Issuance (Retirement) of Debt, Net
    Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
    Alphabet, Inc. Venture Capital 16.555 10549086 0 2023-06-30 LOW
    Fidelity Management & Research Company LLC Investment Advisor 8.1676 5204470 -703168 2023-06-30 LOW
    ARK Investment Management LLC Investment Advisor 8.1614 5200567 49716 2023-09-30 LOW
    Singer (James R) Individual Investor 7.8467 5000000 2535000 2022-12-31
    The Vanguard Group, Inc. Investment Advisor/Hedge Fund 6.4097 4084354 212365 2023-06-30 LOW
    BlackRock Institutional Trust Company, N.A. Investment Advisor 5.3374 3401074 249659 2023-06-30 LOW
    State Street Global Advisors (US) Investment Advisor/Hedge Fund 4.8069 3063032 -286745 2023-06-30 LOW
    Federated Hermes Global Investment Management Corp. Investment Advisor/Hedge Fund 3.7705 2402640 0 2023-06-30 LOW
    Casdin Capital, LLC Hedge Fund 3.7045 2360571 240000 2023-06-30 LOW
    Nikko Asset Management Co., Ltd. Investment Advisor/Hedge Fund 3.3697 2147243 -38614 2023-09-30 LOW
    T. Rowe Price Investment Management, Inc. Investment Advisor 3.2977 2101361 95234 2023-06-30 LOW
    ARCH Venture Partners Venture Capital 3.1525 2008809 0 2023-06-30 LOW
    Baker Bros. Advisors LP Hedge Fund 2.223 1416530 0 2023-06-30 LOW
    Redmile Group, LLC Investment Advisor/Hedge Fund 1.6666 1061960 -58719 2023-06-30 LOW
    JP Morgan Asset Management Investment Advisor 1.5839 1009279 -4761 2023-06-30 LOW
    Wellington Management Company, LLP Investment Advisor/Hedge Fund 1.5319 976128 42961 2023-06-30 LOW
    Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.5014 956727 70956 2023-06-30 LOW
    Avidity Partners Management LP Hedge Fund 1.3788 878600 -473100 2023-06-30 HIGH
    BioImpact Capital LLC Investment Advisor/Hedge Fund 1.3464 857940 54439 2023-06-30 MED
    Fidelity Institutional Asset Management Investment Advisor 1.3212 841910 -77269 2023-06-30 LOW

    Trading calculator

    Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

    Trade commission
    0
    • 1:1
    Leverage
    1:1
    • 20
    • 100
    • 500
    • 1000
    • 10000
    Investment
    Trade size (Leverage x Investement):
    Open

    Close

    Short Long
    Past performance is not a reliable indicator of future results For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)
    Profit/Loss

    For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

    Verve Therapeutics, Inc. Company profile

    About Verve Therapeutics Inc

    Verve Therapeutics, Inc. is a genetic medicines company. The Company is engaged in pioneering a new approach to the care of cardiovascular disease (CVD) transforming treatment from chronic management to single-course gene editing medicines. It is advancing a pipeline of single-course in vivo gene editing programs, each designed to mimic natural disease resistance mutations and turn off specific genes to lower blood lipids. The Company's initial two programs focuses on PCSK9 and ANGPTL3, two genes that regulate levels of blood lipids. Its pipeline of in vivo gene editing programs for atherosclerotic cardiovascular disease (ASCVD) includes VERVE-101 and ANGPTL3. The Company's lead product candidate, VERVE-101, is designed to be a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. Its second program is designed to permanently turn off the ANGPTL3 gene in the liver. ANGPTL3 is a key regulator of cholesterol and triglyceride metabolism.

    Financial summary

    BRIEF: For the fiscal year ended 31 December 2021, Verve Therapeutics Inc revenues was not reported. Net loss increased from $45.7M to $120.3M. Higher net loss reflects Fair Value of antidilution rights increase from $5.4M to $25.6M (expense), Fair Value Adjustment of success payment increase from $2.4M to $7.8M (expense), Interest Income - Non Bank decrease of 12% to $142K (income).

    Industry: Biotechnology & Medical Research (NEC)

    201 Brookline Avenue
    Suite 601
    BOSTON
    MASSACHUSETTS 02215
    US

    Income Statement

    • Annual
    • Quarterly

    News

    December RBA preview: no move expected at the final meeting of 2023

    The RBA meets on Tuesday, 5th of December, 2023, at 2.30 PM (AEDT). We preview what to expect from this month’s decision.

    14:47, 4 December 2023

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    CPI drops more than expected in Europe, Spain’s IBEX 35 looking to break pre-COVID highs

    12:39, 30 November 2023

    Euro Zone CPI expected to continue dropping; economists warn about cutting too soon

    EZ PI expected to drop further but speed of decline

    08:16, 29 November 2023

    A weaker Dollar drives gold higher

    Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

    13:49, 28 November 2023

    Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

    US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

    13:20, 28 November 2023

    RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

    The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

    13:04, 28 November 2023

    Crude prices slide on OPEC+ uncertainty

    Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

    12:55, 28 November 2023

    People also watch

    Oil - Crude

    69.89 Price
    -3.190% 1D Chg, %
    Long position overnight fee -0.0207%
    Short position overnight fee -0.0013%
    Overnight fee time 22:00 (UTC)
    Spread 0.030

    BTC/USD

    44,009.75 Price
    +0.130% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 22:00 (UTC)
    Spread 106.00

    XRP/USD

    0.64 Price
    +1.940% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 22:00 (UTC)
    Spread 0.01168

    US100

    15,789.50 Price
    -0.490% 1D Chg, %
    Long position overnight fee -0.0263%
    Short position overnight fee 0.0041%
    Overnight fee time 22:00 (UTC)
    Spread 1.8

    Still looking for a broker you can trust?

    Join the 570.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading